NetraMark signs first CRO contract to analyze neurodegeneration data
Tweet Send to a Friend
NetraMark Holdings Inc. (TSX: AIAI) (OTCQB: AINMF) signed a contract to analyze phase 2 neurodegeneration clinical trial data through a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
